NEWS AND MEDIA
Recent News
Tinostamustine Shows Early Signals of Activity in Phase 1 Glioblastoma Trial
Data reveals positive preliminary results for investigational agent tinostamustine as a potential first-in-class treatment for glioblastoma. Stamford, Conn. November 19, 2025 – Purdue Pharma L.P. (“Purdue”) announced positive preliminary results from a Phase 1 study…
Bankruptcy Court to Confirm Purdue Pharma’s Plan of Reorganization
STAMFORD, Conn. – November 14, 2025 – The United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) today indicated it will approve the Chapter 11 Plan of Reorganization (The “Plan”) for Purdue Pharma L.P. (“Purdue”). The Plan,…
FDA Grants Orphan Drug Designation for Tinostamustine in Malignant Glioma
This is another recognition in a series of recent milestones for the potential first-in-class investigational drug, including acceptance into the GBM AGILE adaptive clinical trial Stamford, Conn., Nov. 10, 2025 – Purdue Pharma L.P. (“Purdue”) today announced that the…
Purdue Pharma L.P. Plan of Reorganization Receives Overwhelming Creditor Support
Stamford, Conn. – Oct. 21, 2025 – Purdue Pharma L.P. (“Purdue”) today announced that its Chapter 11 Plan of Reorganization (“Plan”) received support from more than 99% of voting creditors, based on preliminary voting results. The votes were calculated by Kroll,…
New Study Examines Nalmefene Auto-Injector and Intranasal Naloxone for Reversal of Respiratory Depression Induced by Fentanyl in a Controlled Clinical Study
The results, published in the Journal of Clinical Pharmacology, support the nalmefene auto-injector as an important treatment option to support emergency opioid overdose reversal STAMFORD, Conn., Sept. 29, 2025 – A pharmacodynamic study sponsored by Purdue Pharma L.P.…
Investigational Drug Tinostamustine to be Included in GBM AGILE Clinical Trial for Glioblastoma
Stamford, Conn., Sept. 17, 2025 – Purdue Pharma L.P. (“Purdue”) has entered into an agreement to have its pipeline medication tinostamustine included in the Phase 2/3 GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) adaptive clinical trial for…
Results from Sunobinop Phase 1B Study in Patients with Interstitial Cystitis/Bladder Pain Syndrome Announced
Data demonstrate positive preliminary results for investigational agent sunobinop as a potential first-in-class treatment for interstitial cystitis/bladder pain syndrome Stamford, CT- September 9, 2025 - Purdue Pharma L.P. (“Purdue”), announced positive preliminary…
Purdue Pharma L.P. Expands its Provision of Low-Cost Opioid Use Disorder Treatment to Correctional Facilities for Incarcerated Individuals
STAMFORD, Conn., Sept. 2, 2025 – Purdue Pharma L.P. (“Purdue”) announced today, in recognition of International Overdose Awareness Day, that the Company has expanded its partnership with MMCAP to provide buprenorphine and naloxone tablets CIII (generic Suboxone®), a…
Purdue Pharma L.P. Receives Court Approval of Disclosure Statement Filed in Connection with its Plan of Reorganization
Plan to deliver more than $7.4 billion of creditor distributions Company to begin creditor vote solicitation process; voting deadline set for September 30, 2025 Stamford, Conn. – June 20, 2025 – Purdue Pharma L.P. (“Purdue”) today announced that the United States…
Purdue Pharma L.P. Files New Plan of Reorganization Providing for More Than $7.4 Billion in Creditor Distributions
Sacklers to contribute approximately $6.5 – $7 billion, $1 billion more than under previous Plan $2.4 billion of cash expected to be distributed on the effective date Company assets will be transferred to new public benefit company dedicated to abating the opioid…